TScan Therapeutics
Waltham · Founded 2018
About TScan Therapeutics
TScan is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Company Facts
- Founded: 2018
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $410.0M
- Funding stage: IPO
- Last round: Post-IPO Equity (Dec 2024)
- Ticker: nasdaq:TCRX
- Website: https://www.tscan.com/
- Phone: 857-399-9500
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/tscan-therapeutics-95845 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.